Corinna Grisostomi

USPTO Granted Patents = 21 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 19 (Patent Applications = 20)

Average Co-Inventor Count = 6.5

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

14 out of 217

Actelion Pharmaceuticals Ltd

patents

7 out of 77

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2010-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410208 - (2-acetamidyl)thio-beta-D-galactopyranoside derivatives (2025-09-09),

2. 12404295 - (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives (2025-09-02),

3. 12319672 - Alpha-D-galactopyranoside derivatives (2025-06-03),

4. 12312362 - Spiro derivatives of Alpha-D-galactopyranosides (2025-05-27),

5. 12304902 - Hydroxyheterocycloalkane-carbamoyl derivatives (2025-05-20),

6. 12291520 - Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives (2025-05-06),

7. 12291519 - 2-hydroxycycloalkane-1-carbamoyl (2025-05-06),

8. 10189839 - Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase (2019-01-29),

9. 9765092 - Tricyclic piperidine compounds (2017-09-19),

10. 9346793 - Hydroxylated aminotriazole derivatives as ALX receptor agonists (2016-05-24),

11. 9187435 - Bridged Spiro[2.4]heptane ester derivatives (2015-11-17),

12. 8846733 - Oxazolyl-methylether derivatives as ALX receptor agonists (2014-09-30),

13. 8674111 - Oxazole and thiazole derivatives as ALX receptor agonists (2014-03-18),

14. 8580831 - Fluorinated aminotriazole derivatives (2013-11-12),

15. 8563714 - Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists (2013-10-22),

Title: Corinna Grisostomi: Innovator in Pharmaceutical Chemistry

Introduction

Corinna Grisostomi, based in Allschwil, Switzerland, is a prominent inventor in the field of pharmaceutical chemistry, holding an impressive total of 19 patents. Her contributions significantly advance the development of novel therapeutic agents, particularly in the area of Galectin-3 inhibitors.

Latest Patents

Among her latest inventions are the "Alpha-D-galactopyranoside derivatives", which involve compounds characterized by specific structural formulas and their preparation methods. These compounds not only include various functional groups but also demonstrate potent activity as pharmaceutical agents, particularly for inhibiting Galectin-3. Another noteworthy patent is for "Spiro derivatives of Alpha-D-galactopyranosides," which similarly focuses on the development of compounds that are crucial for pharmaceutical compositions designed to combat diseases associated with Galectin-3.

Career Highlights

Corinna has had a distinguished career, contributing her expertise to leading pharmaceutical companies, including Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. Her work has been pivotal in transforming scientific research into viable medical solutions, establishing her as a leading figure in the industry.

Collaborations

Throughout her career, Corinna has collaborated with notable professionals such as Daniel Bur and Olivier Corminboeuf. These partnerships have fostered a rich exchange of ideas and innovation, further enhancing her research outcomes and the overall impact of her work in pharmaceutical sciences.

Conclusion

Corinna Grisostomi exemplifies the spirit of innovation in modern pharmaceutical research. With her extensive patent portfolio and collaborations, she continues to contribute valuable advancements to the medical field, offering promising solutions for various health challenges. Her ongoing work inspires future generations of inventors and researchers striving to improve global health outcomes.

This text is generated by artificial intelligence and may not be accurate.